Pharmacological C3 complement inhibition (myelofibrosis)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-08-25 — Spatial profiling of the spleen in mouse and human myelofibrosis reveals complement-driven immune-stromal interactions as a therapeutic target.: Preclinical spatial profiling of mouse and human myelofibrotic spleens identified C3-dependent reprogramming of splenic reticular cells into inflammatory pro-fibrotic states driving extramedullary niches; genetic or pharmacologic C3 blockade reduced splenomegaly and bone marrow fibrosis. (novelty: 5)
Open questions
Related
Contributing findings
Spatial profiling of the spleen in mouse and human myelofibrosis reveals complement-driven immune-stromal interactions as a therapeutic target.
25-aug-2026
novelty 5
per-area 5
introduces